Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT02448173
PHASE3

A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

Sponsor: Vaccinogen Inc

View on ClinicalTrials.gov

Summary

OncoVAX® is the first cancer therapy that both prevents cancer recurrence and addresses the diversity of cancer cells. In this pivotal randomized, multicenter Phase IIIb study in patients with Stage II colon cancer, OncoVAX is designed to use a patient's own cancer cells to mobilize the body's immune system to prevent the return of colon cancer following surgery.

Official title: A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

550

Start Date

2026-08

Completion Date

2033-08

Last Updated

2026-02-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

OncoVAX and Surgery

OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer

PROCEDURE

Surgery

Surgical resection of Stage II colon cancer

Locations (1)

Halifax Health Medical Center

Port Orange, Florida, United States